Novartis: FDA accepts review for migraine drug.

(CercleFinance.com) - Novartis said on Thursday US regulators had accepted its marketing application for erenumab, aimed at preventing migraine in patients experiencing four or more migraine days per month.


If approved, erenumab is expected to be the first and only fully human monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, which is specifically designed for the prevention of migraine.

Erenumab would be jointly marketed in the US by Amgen and Novartis.

Copyright (c) 2017 CercleFinance.com. All rights reserved.